Market Research Reports and Industry Reports

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
 
Summary
 
Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.
 
 In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%. The US will have the highest number of five-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively.
 
 This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72).
 
 Scope
 

 - The brain cancer EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). This report includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma).
 - The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
 - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
 
 Reasons to buy
 
 The brain cancer EpiCast report will allow you to - 
 - Develop business strategies by understanding the trends shaping and driving the global brain cancer market.
 - Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.
 - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

 2 Introduction 7
 2.1 Endoscopic Instruments Overview 7
 3 Products under Development 8
 3.1 Endoscopic Instruments - Pipeline Products by Stage of Development 8
 3.2 Endoscopic Instruments - Pipeline Products by Territory 9
 3.3 Endoscopic Instruments - Pipeline Products by Regulatory Path 10
 3.4 Endoscopic Instruments - Pipeline Products by Estimated Approval Date 11
 3.5 Endoscopic Instruments - Ongoing Clinical Trials 12
 4 Endoscopic Instruments - Pipeline Products under Development by Companies 13
 4.1 Endoscopic Instruments Companies - Pipeline Products by Stage of Development 13
 4.2 Endoscopic Instruments - Pipeline Products by Stage of Development 14
 5 Endoscopic Instruments Companies and Product Overview 15
 5.1 Agile EndoSurgery, Inc. Company Overview 15
 5.1.1 Agile EndoSurgery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 15
 5.2 ARTANN Laboratories, Inc. Company Overview 16
 5.2.1 ARTANN Laboratories, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
 5.3 Beacon Endoscopic Inc. Company Overview 19
 5.3.1 Beacon Endoscopic Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
 5.4 BioTex, Inc. Company Overview 20
 5.4.1 BioTex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 20
 5.5 Boston Scientific Corporation Company Overview 21
 5.5.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 21
 5.6 Bovie Medical Corporation Company Overview 26
 5.6.1 Bovie Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 26
 5.7 Endeau Inc. Company Overview 28
 5.7.1 Endeau Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
 5.8 Endo Tools Therapeutics S.A. Company Overview 29
 5.8.1 Endo Tools Therapeutics S.A. Pipeline Products & Ongoing Clinical Trials Overview 29
 5.9 Endogene Ltd Company Overview 33
 5.9.1 Endogene Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
 5.10 Endoscape, Inc. Company Overview 35
 5.10.1 Endoscape, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
 5.11 Gordian Surgical, LLC Company Overview 38
 5.11.1 Gordian Surgical, LLC Pipeline Products & Ongoing Clinical Trials Overview 38
 5.12 KARL STORZ GmbH & Co. KG Company Overview 39
 5.12.1 KARL STORZ GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 39
 5.13 Merit Medical Systems, Inc. Company Overview 41
 5.13.1 Merit Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
 5.14 Resultados y Calidad del Sistema Sanitario Publico de Andalucia Company Overview 43
 5.14.1 Resultados y Calidad del Sistema Sanitario Publico de Andalucia Pipeline Products & Ongoing Clinical Trials Overview 43
 5.15 SMART Medical Systems Ltd. Company Overview 44
 5.15.1 SMART Medical Systems Ltd. Pipeline Products & Ongoing Clinical Trials Overview 44
 5.16 Softscope Medical Technologies, Inc. Company Overview 47
 5.16.1 Softscope Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
 5.17 Temple University Health System Company Overview 48
 5.17.1 Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 48
 5.18 The Johns Hopkins University Company Overview 49
 5.18.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 49
 5.19 The Pennsylvania State University Company Overview 51
 5.19.1 The Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 51
 5.20 TransEnterix, Inc. Company Overview 53
 5.20.1 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
 5.21 University of Arizona Company Overview 55
 5.21.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 55
 5.22 Verisante Technology, Inc. Company Overview 57
 5.22.1 Verisante Technology, Inc. Pipeline Products & Ongoing Clinical Trials Overview 57
 6 Endoscopic Instruments- Recent Developments 60
 7 Appendix 75
 7.1 Methodology 75
 7.2 About GlobalData 77
 7.3 Contact Us 78
 7.4 Disclaimer 78


List Of Tables

 Table 1: Description of Brain Cancer Types 10
 Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer 15
 Table 3: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer 16
 Table 4: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024 22
 Table 5: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N (Row %), 2014 24
 Table 6: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N (Row %), 2014 26
 Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014?2024 29


List Of Figures

Figure 1: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Men, 1998-2007 12
Figure 2: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Women, 1998-2007 13
Figure 3: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024 23
Figure 4: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N, 2014 25
Figure 5: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N, 2014 27
Figure 6: 7MM, Age-Standardized Diagnosed Incidence of Brain Cancer, All Ages, N, 2014 28
Figure 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014?2024 30
Figure 8: 7MM, Diagnosed Incident Cases of Brain Cancer by Type, All Ages, Both Sexes, N, 2014 31


EpiCast Report: Endometriosis - Epidemiology Forecast to 2025

EpiCast Report: Endometriosis - Epidemiology Forecast to 2025Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in

USD 3995View Report

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025Schizophrenia is a severe mental disorder that affects an individuals behaviors, thoughts, and emotions; it is extremely heterogeneous, and no two affected individuals

USD 3995View Report

EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025

EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses resulting in mild to severe influenza-like illness.

USD 3995View Report

EpiCast Report: Endometriosis - Epidemiology Forecast to 2025

EpiCast Report: Endometriosis - Epidemiology Forecast to 2025Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in

USD 3995View Report

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025Schizophrenia is a severe mental disorder that affects an individuals behaviors, thoughts, and emotions; it is extremely heterogeneous, and no two affected individuals

USD 3995View Report

EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025

EpiCast Report: Seasonal Influenza - Epidemiology Forecast to 2025Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses resulting in mild to severe influenza-like illness.

USD 3995View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 3995
  • Site Licence    $ 7990
  • Enterprise Wide Licence    $ 11985
$ 3995

Reports Details

Published Date : Dec 2015
No. of Pages :42
Country :Global
Category :Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment